Mazdutide
IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist
37 Amino Acids · MW: ~5,000 Da
Amino Acids
37
Molecular Weight
~5,000 Da
Half-life
5-7 days
Research Score
4.5
Studies
28
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Mazdutide?
Mazdutide is a long-acting oxyntomodulin-inspired dual agonist being developed for obesity and metabolic disease. It is designed to drive clinically meaningful weight loss while improving glucose and lipid parameters.
Key Benefits & Mechanisms
clinically meaningful weight loss
better glycemic control
reduced waist circumference
improved lipid profile
Research Summary
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Related Peptides
Oxyntomodulin
Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide
Oxyntomodulin is a naturally occurring proglucagon-derived peptide that activates GLP-1 and glucagon pathways. It is a key research tool for appetite suppression and energy balance studies in obesity.
Weight ManagementCotadutide
MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist
Cotadutide is a synthetic oxyntomodulin analogue designed to engage both GLP-1 and glucagon receptors. It was developed to improve weight loss and metabolic markers in obesity and type 2 diabetes research.
Weight ManagementDulaglutide
Recombinant GLP-1 receptor agonist Fc fusion protein
Dulaglutide is a long-acting GLP-1 receptor agonist used primarily in type 2 diabetes. It consistently produces modest weight loss and is widely studied as a benchmark incretin mimetic.
Weight ManagementLixisenatide
Exendin-4-derived GLP-1 receptor agonist
Lixisenatide is a short-acting GLP-1 receptor agonist derived from exendin-4. It is best known for postprandial glucose control, with modest secondary weight loss in clinical use.
Weight Management